Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
THE ALENDRONATE DISCONTINUATION STUDY (ALEXIS)
2023-510042-24-01Phase 4Authorised
- Sponsor
- University Hospital Odense
- Start
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of alendronate in osteoporosis, sponsored by University Hospital Odense. Primary endpoint: Incidence of fragility fractures during the study period. Planned start Jul 2024; status: authorised.
02
Drugs
alendronate
03
Conditions
osteoporosis
Beyond the preview
Go deeper on 2023-510042-24-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-510042-24-01.